IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin
Parikshit Bansal, Chandrashekhar Honrao and Uttam C. Banerjee
Affiliation: Department of Pharmaceutical Technology Biotechnology (PTBT), National Institute of Pharmaceutical Education and Research (NIPER), Phase X, Mohali-160062 India.
Keywords: Hemoglobin, haemoglobin, biopharmaceutical recombinant formulation, cross-linking, polymerization, blood substitute, recombinant hemoglobin, patents
Hemoglobin, the protein responsible for the red color of blood plays a very important part in ‘life’- it transports oxygen, without which humans cannot survive. The idea of using purified Hemoglobin as a possible universal substitute for red blood cells has been around for almost a century. Hemoglobin formulations have important therapeutic applications, especially in case of trauma and war when requirements for blood may be very large. Manufacture of hemoglobin for use as a biopharmaceutical poses practical challenges, owing to dependence on human expired blood and fragility of the protein molecule. Biotechnology can play a critical role in breaking these barriers, by not only ensuring recombinant production of hemoglobin, but also enhancing stability of the molecule. The present article, based on a review of patents and available literature gives an insight into the IPR and technological issues involved in the commercial production of this ‘life-saving’ protein. There are more than 250 patents worldwide related to hemoglobin formulation, crosslinking and determination.
Rights & PermissionsPrintExport